Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Akebia Ther (AKBA)

NASDAQ
Currency in USD
Disclaimer
1.830
-0.410(-18.30%)
Closed
After Hours
1.870+0.040(+2.186%)

AKBA Comments

target min.2.95$
company have big and bright future
because uk aproval this company have second breath.buy now and fly to the moon trust me
Kindly I am in deep sh*** sfter the sotck drops from 2.20 too 0.61c my lost is huge:( any kind info about the Company future.
My calls expired worthless last week. Time to go Up!
same situation with many. next earning date on May 10th. Will get some idea before a week of this report. Will hold this scrip until.
Kindly I am in deep sh*** sfter the sotck drops from 2.20 too 0.61c my lost is huge:( any kind info about the Company future.
My dream jobs is analyst. I would downgrade stocks after the drop and upgrade after the rip 8 days / hour for a large salary.
fda=mafia
Towards bankruptcy
Chart points to 1st target $5
should I buy the dip ? is it worth it ?
Do you like bets? I bought the dip, but it's going deeper...
I bought the dip a while back and then it diped even lower and now Im not sure to get the dip again lol
meanwhile, some good news...
Guys, any ideas where it’s heading?
But when NDA news will arrive next month this maybe will be a dollar stock... Any idea why is dropping every day???
They have 2 NDA fillings due by mid 2nd Q, so around May
Sooon it will go up
When 😛😛😛😛😛🤭🤭🤭
Seems good news are on the way, just need to check Fibrogen, downgraded quite badly
1º Institutions loading up, 2º They Hired many ppl , sales team included, 3º They hired Mrs Zumwalt who was Vice president & Government Affairs at DaVita. Why he joined AKBA if they didn´t have a good chance to be a major player. it could literally ruin his entire carrer 4º $FGEN one os his biggest competitors has a "inconclusive " data results & enormous market cap compare to his sales. 5º Vadadustad already aprroved in Japan 6º Distribution Agreement signed which is huge advantage. 7º They are trying to get in European & chinease markets
entry for 3.30 n below
Akebia Therapeutics Appoints LeAnne M. Zumwalt, Dialysis Industry Leader, to Board of Directors
https://finance.yahoo.com/news/akebia-therapeutics-appoints-leanne-m-130000588.html
http://www.conferencecalltranscripts.org/summary/?id=8923411
target price long term : 6.50 - 8.00mid term : 4.85 - 5.85cut loss : 3.75
Are you sure it isn´t heading to 9-12 ??
from the charts.. mid term goals target for above 4.85 range has reach and making towards 5.85...heading towards 9 to 12 maybe 50/50 chance..we wait for the second target that is 6.50 n above..else should find CL n go to other counter ..
from the charts.. mid term goals target for above 4.85 range has reach and making towards 5.85...heading towards 9 to 12 maybe 50/50 chance..we wait for the second target that is 6.50 n above..else should find CL n go to other counter ..
4.09
Have a look this link guys : https://www.clinicaltrials.gov/ct2/show/NCT04478071?term=vadadustat&draw=2&rank=10
to the moon!
It will be parabolic if they get approved by FDA. It is a really good investment
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.